Dolthera GmbH

Dolthera GmbH, which operated under the name Avontec GmbH in Martinsried, Germany, was a biopharmaceutical firm concentrated on developing treatments for inflammatory diseases. The company's primary focus was on the research and development of medicinal products to control the expression of genes relevant to diseases, utilizing transcription factor technology. Dolthera's lead programs, AVT-01 for asthma and AVT-02 for psoriasis, had advanced into Phase 2a clinical trials. The company's business activities also included providing advisory and training services in its field and commercializing the methods, knowledge, and products it developed.

The company appears to be defunct. It had secured a total of $25.1 million in funding over three rounds, with its first round on September 25, 2002, and its final grant round on September 25, 2008, which raised $836,000. Its investors included entities such as Mediport Venture Funds, BMBF, BioMedPartners, and KfW.

It is important to note that the domain avontec.com is now associated with Avontec Automation Private Limited, an unrelated Indian company established in 2019 that specializes in industrial automation and digital transformation. This engineering firm provides solutions like robotics, system integration, and various industrial display products for sectors including food & beverage, pharmaceuticals, and automotive.

Keywords: Dolthera GmbH, Avontec GmbH, biopharmaceutical, inflammatory diseases, transcription factor technology, drug development, clinical trials, AVT-01, asthma treatment, AVT-02, psoriasis treatment, Martinsried, defunct, venture capital, life sciences, small molecule therapeutics